Pharma deals pivot from high-risk modalities, targets

Editor in Chief Simone Fishburn selected this story as one of BioCentury's Best of 2024. To see the full list, click here.

The past 12 months have brought a surge in pharma dealmaking, and with that comes evidence of changes in external innovation objectives among the top pharmas. The first-in-class strategies that have defined dealmaking in recent years are giving way to best-in-class priorities. ...